Abstract Sepsis continues to escape a precise diagnostic definition. The most recent consensus definition, termed Sepsis-3, highlights the importance of the maladaptive and potentially life-threatening host response to infection. After briefly reviewing the history and epidemiology of sepsis, we go on to describe some of the challenges encountered when classifying such a heterogenous disease state. In the context of these new definitions for sepsis and septic shock, we explore current and potentially novel therapies, and conclude by mentioning some of the controversies of this most recent framework.
Introduction
The new Sepsis-3 consensus definitions firmly acknowledge the role of the host response to infection [1] . In this article we review the pathophysiology and epidemiology of sepsis with respect to the new definitions and explore some of the historical challenges that characterize the nomenclature of sepsis. We touch on current and emerging therapies as well as some of the research against the backdrop of Sepsis-3. Our account concludes by highlighting some of the controversies of this new consensus framework.
Sepsis Overview: Pathology and Epidemiology
A satisfactory clinical definition of sepsis remains elusive and continues to be an imprecise diagnostic term since its first description by the ancient Greeks [2, 3] . Etymologically, sepsis means to decay or to putrefy. The language defining sepsis has been riddled by heterogeneous terminology, and various criteria have been put forward attempting to facilitate early identification and allow definitive diagnosis [4] .
Thus, sepsis continues to be a descriptive and varied syndrome without, at present, a validated gold-standard criterion or established diagnostic test, consequently leading to huge variations in the reported incidence and mortality rates [5] . However, there is little doubt that sepsis is a common worldwide, transcending age, geography, race or pre-existing health status [6] [7] [8] . The Centers for Disease Control and Prevention (CDC) has conservatively estimated the annual incidence of severe sepsis to be 50-100 cases per 100,000 persons, with absolute numbers averaging approximately 1,141,000 cases of sepsis in the US in 2008 [6, 8, 9] . Figures for the UK have recently estimated 200,000 cases of sepsis a year [10] . Although these figures are in the context of ever-increasing incidence rates internationally, they are not free of controversy. The lack of consistency in defining sepsis, organ dysfunction and septic shock, possible reporting bias fueled by incentivized coding, as well as previous underreporting, make the data difficult to interpret. Complicating matters further, improvements in diagnosis and the increasing ability to care for the most critically ill patients may further explain the huge variations in the incidence of sepsis [1, 5] . Despite the true incidence of sepsis remaining unknown, there is little argument that mortality remains high, with a mortality rate of 35% quoted for the UK [10] [11] [12] . This is mirrored by figures from the US that put mortality between 30 and 50%, making it the leading cause of death and morbidity in intensive care units [6] [7] [8] . The escalating cost of treating sepsis is measured in billions of dollars yearly in the US alone, with expenses most often incurred during weeks or month-long admissions in critical care units [8, 9] . Moreover, sepsis is now being increasingly recognized to contribute to a significantly reduced quality of life in those who survive their acute illness, with neuromuscular weakness, reduced functional status, depression, anxiety and post-traumatic stress syndrome commonly reported [13] . Unlike many other epidemic diseases, treatment for sepsis is non-specific and is largely based on supportive care, including oxygen, intravenous fluids, antibiotics, vasopressors, inotropes and mechanical organ support, along with surgical or radiological source control where possible. There are currently no clinically approved biological agents that modify the pathophysiology and specifically target sepsis [14] .
Against this backdrop, the biology of sepsis continues to be incompletely understood. Complex pathophysiology in response to infection is at play, involving both pro-and anti-inflammatory pathways, as well as a whole array of non-immunological mechanisms [15] . It is increasingly becoming clear that sepsis is an intricate syndrome characterized by the pathogen as well as the host response. Thus, sepsis is now thought of as organ dysfunction driven by a dysregulated host response secondary to infection. The advances made in understanding the pathophysiology of sepsis have been fundamental in the creation of the new Sepsis-3 guidelines. [1] .
History of the Definition of Sepsis
The difficulty of defining sepsis accurately and consistently is well-documented [4, 5] . In everyday clinical language the terminology surrounding sepsis is used in a whole variety of ways and is commonly used colloquially to mean severe infection or infection generally. The first real attempt to define a set of clinical parameters characterizing patients with sepsis came in 1989 when Roger Bone and colleagues proposed the term sepsis syndrome (Table 1 ) [4] .
Following on from the sepsis syndrome concept, the American College of Chest Physicians (ACCP) and the Society of Critical Care Medicine (SCCM) convened a consensus conference in 1991 attempting to create a set of standardized definitions [16] . According to the ACCP-SCCM, infection was defined as a microbial phenomenon characterized by the invasion of microorganisms or microbial toxins into normally sterile tissues [16] . The key term that emerged at the end of this conference was the systemic inflammatory response syndrome, known as SIRS. SIRS followed on from the sepsis syndrome using clinical values to identify physiological features consistent with inflammation considered a hallmark feature of sepsis [4, 16] . The SIRS criteria were established, by consensus, Thus, SIRS represented a systemic inflammatory response of any aetiology, including sepsis. Therefore, sepsis was defined by the presence of SIRS in association with a confirmed/suspected infection; sepsis associated with organ dysfunction was called severe sepsis; and, in turn, septic shock was termed severe sepsis with sepsisinduced hypotension persisting despite adequate fluid resuscitation (Table 3 ) [16] .
In order to classify this consensus statement in relation to more recent definitions, it has subsequently been referred to as Sepsis-1. Sepsis-2 followed on in 2001 and was proposed at the Sepsis Definition Conference. The SIRS criteria were thought to be overly sensitive and nonspecific and a whole list of signs and symptoms were added to better illustrate severe sepsis and septic shock in particular [17] . The predominant aim was to improve the SIRS-based criteria in their description of the clinical response to infection. Unlike the 1991 definition, there was an increasing understanding that it was the host response to microorganisms that characterizes sepsis as a clinical phenomenon [4] .
The Sepsis-3 definition incorporates this concept as a fundamental principle. Thus, the latest definitions reflect an improved attempt at conceptualizing the double imperative that sepsis needs to be recognized early and is a dysregulated host response in the face of infection [1] . The Sequential Organ Failure Assessment (SOFA) tool is used by this latest framework to quantify the host response (see Box 1) [1, 18] .
Improving Outcomes: Human Factors
Over recent years, interest in human factors has steadily increased across healthcare [19] . Specifically, analysis of human factors is a science at the crossroads of psychology and engineering. Its role in healthcare is to support performance and promote high-quality, safe care for patients; this has become something of a mantra in 21st century medicine [20] .
Establishing validated diagnostic criteria such as Sepsis-3, designing sepsis care bundles, and publishing national as well as international guidelines on the management of sepsis are all attempts to improve clinical outcomes. Teaching, resuscitation courses and early warning scores aim to complement these efforts. Increasingly, specialized hospital teams such as rapid response or critical care outreach are seen as an integral part of the early detection and intervention in sepsis promoted by organizations such as the Surviving Sepsis Campaign [21] . Despite significant improvements in critical care outcomes, mortality rates in sepsis remain frustratingly high [12] . Teaching, practice guidelines and international campaigns have not proven to be the entire answer.
Problems with Trial Design
Randomized trials are widely accepted as the most valid method of evaluating the effectiveness of medical management, including the testing of therapeutic interventions; however, trials are difficult to perform, and are time-consuming and costly [22] . Moreover, the history of therapeutic studies in sepsis has been marked by substantial efforts at reducing mortality, but all recent large-scale effectiveness trials have failed to demonstrate improved survival [23] . Although incidence rates vary widely, mortality for sepsis is generally thought to be declining over the last decade or so [23] ; however, it is difficult to say how accurate these conclusions are. Variations in sepsis incidence rates associated with inconsistent sepsis criteria significantly affect mortality figures. Nonetheless, the reduction in mortality has been empirically attributed to improved processes of care, such as earlier diagnosis, timely resuscitation and low tidal volume ventilation [23] . The statistical power of trials is dependent on a number of variables, including the population's baseline risk, treatment effect size and modifiable mortality [22, 23] . As the overall mortality rate declines in the general sepsis population, the potential absolute effect of any given treatment is reduced. Unintentional recruitment of low-risk populations, as well as intentional exclusion of patients at risk of imminent death, compounds matters further [23] .
As alluded to earlier, sepsis is a complex syndrome characterized by the intricate interaction of many pathways and physiological networks. Simplistically speaking, therapeutic interventions in sepsis must either control a multitude of pathways with several interventions or, alternatively, target single nodal points that control a number of pathways [23] . Currently, most trials evaluating pharmacological interventions target single pathways. It is highly uncertain, in the context of emerging evidence, whether treatments targeting a single aspect of sepsis can be reasonably expected to reduce all-cause mortality [22, 23] .
Furthermore, all-cause mortality is a powerful clinical endpoint when assessing the net benefit of a treatment when most deaths can be unambiguously attributed to the disease being studied. However, in sepsis, death occurs in many ways and is often unrelated to the therapy being evaluated. In the intensive care arena, variations in approaches to the withdrawal of life-sustaining therapies is just one example. Although true randomization should deal with many of these confounders, it does increase the challenge. This heterogeneity in sepsis trials extends to almost all other aspects, not just mortality, and is mapped out in Table 4 [22] [23] [24] .
Current Role and Future Prospects of Pharmacologicals
The goals of pharmacotherapy in sepsis can be summarized as follows: eradication of the infection; reduction in the impact of the maladaptive septic state; and prevention of complications. Current drug therapy for sepsis focuses around a few key timely interventions, namely antibiotics, fluids and drugs supporting the circulation. Despite theoretical models and in vitro assays showing some promise, there continues to be an absence of pharmacological agents modulating the deleterious effects of the host response [14, 24] . The only agent recently available to clinicians was recombinant activated protein C (Xigris Ò ; Eli Lilly and Co., Indianapolis, Indiana 46285, USA), which has now been discontinued following concerns over the risks of intracerebral bleeding, with no difference in all-cause mortality at 28 days compared with placebo [25] . Despite significant advances in understanding the pathophysiology of sepsis encapsulated by Sepsis-3, the therapeutic options have remained largely unchanged.
Antibiotics
The premise of initial empirical antimicrobial therapy is that it must be comprehensive and should cover all likely pathogens relevant to the clinical setting [12] . Given that sepsis is caused by the effects of microorganisms and the interaction of toxic mediators with the host, knowledge regarding the most common pathogens involved is needed to guide the selection of empirical antibiotics [12] . Hence, microbiological sampling is key in steering antibiotic selection, identifying inadequate cover, and helping subsequent de-escalation of therapy and thereby reducing the risk of complicated secondary infection [26] .
Current recommendations in the UK state that unless microbiological sampling is likely to significantly delay antimicrobial administration, at least one set of blood cultures should be taken [26] . Early administration of antibiotics is recommended, although many patients present late with established organ dysfunction and septic shock [27] . Rapid and early sampling may be feasible for blood, urine and sputum, but for more invasive sampling, such as biopsy or lumbar puncture, these are likely to be acquired later and hence after antibiotics have been administered. Antimicrobial therapy in general is based on the differential cellular make-up between eukaryotes and prokaryotes, which gives them a degree of therapeutic specificity. Broadly speaking, these differences relate to the cell wall and its synthesis, their ribosomal machinery and their DNA synthetic pathways [28] . Clinically, and much more simplistically, this translates into administration of broad-spectrum antibiotics covering Gram-positive, Gramnegative and anaerobic bacteria. Once the causative organism has been identified, the antibiotics are tailored to the pathogen. With the emergence of increasingly resistant organisms, and concerns around strains that are resistant to all known antibiotics, it has become of paramount importance to identify new drug target sites in conjunction with good antibiotic stewardship [21, 26] .
Recent advances in the understanding of the lipopolysaccharide structure of the outer leaflet of Gramnegative bacteria and its enzymology may prove to be theoretically interesting targets for novel antibiotics [28, 29] . As ever, translating these pathobiological concepts into clinical reality takes time and considerable effort, a luxury that can be ill-afforded in the face of exponential Darwinian bacterial evolution. Thus, although the definitions proposed by Sepsis-3 are not going to change the antibiotic management of sepsis per se, their impact may be indirect through earlier detection and intervention.
Earlier identification of sepsis and conceptual clarity reflecting everyday clinical language may result in more timely administration of antimicrobials. Encouraging clinicians to consider sepsis in the differential diagnosis and streamlining definitions is commendable. There is however a trade-off between optimizing the capture rate versus overdiagnosis, and thus potentially risking both the overuse of broad-spectrum antibiotics and promotion of multiresistance while worsening cost effectiveness.
Fluids
Fluid administration in sepsis has been controversial, with various areas of contention, including type, amount and resuscitation endpoints [30] . Large volumes of fluid continue to be administered in areas outside the intensive care unit where monitoring of effect, and perhaps expertise, is limited [31] . Debate about the type of fluid is unlikely to cease soon; starch-based solutions are now rarely licensed, indicated or used for sepsis in view of their association with renal impairment and disorders of coagulation [30] . Human albumin solutions have been available in clinical medicine for over half a century but their role in sepsis remains contentious. Both the EARSS and ALBIOS trials established the relative safety profile of albumin administration in sepsis [32, 33] ; however, arguments whether albumin reduces mortality in sepsis are ongoing. Thus, currently, the fluids of choice in the first instance are crystalloid solutions [30, 31] . Earlier identification of sepsis may result in shorter periods of shock but may also result in overenthusiastic fluid administration unless properly supervised. The harmful effects of aggressive fluid resuscitation on the outcome of sepsis have been observed in a number of experimental studies and clinical trials [31, 34, 35] . The most compelling data that fluid loading in sepsis may be harmful comes from the FEAST study performed in Sub-Saharan children with severe sepsis [36] . In this randomized study, fluid bolus administration was associated with a significantly increased risk of death [36] . The Early Goal Directed Therapy (EGDT) trial of Rivers et al. formed the basis for early aggressive fluid resuscitation, but since then important trials such as PROCESS, ARISE and PROMISE have challenged the concept of heavily protocolized EGDT fluid administration and cardiovascular management [34] [35] [36] [37] [38] [39] [40] .
Increasingly, haemodynamically guided, restrictive fluid resuscitation strategies in patients with sepsis and septic shock are advocated [31] . Fluid resuscitation should be informed by fluid responsiveness, preferably using dynamic assessment of the cardiovascular system such as the passive leg raise. Indeed, it can be argued that only volume responsive patients should receive fluid boluses [31] . Sepsis-3 does not address the controversies around fluid administration and thus is unlikely to alter any of these deliberations any time soon.
Vasoactive Medication
Septic shock is defined by Sepsis-3 as sepsis with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) C65 mmHg, and having a serum lactate level [2 mmol/L (18 mg/dL) despite adequate volume resuscitation [1] . Currently, no study has presented statistically significant survival benefit of one vasopressor over another; hence, the choice of vasopressor in septic shock remains empiric [41] .
A recent meta-analysis has demonstrated an 11% reduction in 28-day all-cause mortality with noradrenaline compared with dopamine, with dopamine demonstrating a twofold increase in arrhythmias, which may account for the difference in mortality [41] [42] [43] . No mortality benefit was identified in the comparison of noradrenaline and adrenaline, a finding corroborated in other head-to-head trials [42, 44] . No statistically significant improvement in mortality was observed in a comparison between vasopressin and adrenergic vasopressors (noradrenaline, dopamine), although an overall trend towards reduced mortality with noradrenaline was seen in all comparisons [41, 45] . Most recently, the VANISH study examining the use of early vasopressin versus noradrenaline again showed no improvement in mortality; however, despite not being the primary endpoint, a significant reduction in the use of renal replacement therapy in the vasopressin group was observed [46] .
Overall, the literature is complex and should be interpreted with caution. Many trials use differing clinical outcomes and comparators, making firm conclusions about side effects, length of stay, ventilator-free days, etc., almost impossible. Moreover, data regarding clinical and haemodynamic measurement have been reported inconsistently, and large variations in concomitant fluid administration between trials have been noted, as well as considerable heterogeneity in the source of sepsis [41, 42] . Trials investigating novel vasopressors such as selepressin (NCT02508649) are currently eagerly awaited but are unlikely to address all the uncertainties surrounding vasopressors in sepsis [47] . Based on current trial data, the surviving sepsis guidelines recommend noradrenaline as first-line therapy in septic shock [21] .
Biologicals
Currently, there continues to be no approved drug specifically targeting sepsis [14] . With the emerging complexities in the pathophysiology of sepsis, it is highly unlikely that a single therapeutic agent will provide the magic bullet [24] . Recent advances in molecular diagnostics, biomarkers, genomics, and novel pharmacological agents have hailed some promise in the research arena but are not yet clinical reality [14] .
Biomarkers and Molecular Markers
The current diagnosis of sepsis relies on non-specific physiological criteria and microbiologically-led pathogen detection. Biomarkers presently available to clinicians offer no diagnostic certainty to fundamental questions such as [48] : This diagnostic uncertainty has very real clinical implications, potentially delaying the administration of antibiotics or increasing the overuse of antimicrobial agents [48] . Therefore, there is an increasing need for new sepsis biomarkers that can aid clinicians in rapid therapeutic decision making, risk stratification and monitoring response to therapy. It is hoped that it will not only improve management of sepsis but also drive drug development [48] .
By definition, sepsis biomarkers should reflect the biology of sepsis. A large number of biomarkers have been studied in a variety of research settings and many have demonstrated some propensity to be clinically useful but invariably suffer from some drawback [49] . Most biomarkers can be broadly categorized into biochemical (e.g. complement, coagulation system), cellular elements (e.g. neutrophils, macrophages) and mediators (e.g. cytokines, chemokines).
Cytokines and chemokines, for example, have some value in the assessment of the inflammatory response but lack the discriminative power to differentiate between infectious and non-infectious inflammation [48] [49] [50] .
Coagulation factors (protein C, protein S, antithrombin) have been studied but are limited by the fact that these are frequently activated in other disease states such as trauma, cancer and obstetrics [50] . Soluble receptors and cell surface markers such as triggering receptor expressed on myeloid cells 1 (sTREM-1) have shown some promise but have not yet been prospectively evaluated in large trials [51] .
Questions also remain around procalcitonin and C-reactive protein, which are currently the only biomarkers in widespread clinical use. Both C-reactive protein and procalcitonin have limited abilities to distinguish sepsis from other inflammatory conditions or to predict outcome [46] [47] [48] [49] .
Overall, more than 170 different biomarkers have been assessed for potential use in sepsis, predominantly focusing on prognostic markers as opposed to diagnostic markers. Unfortunately, none of the biomarkers are sufficiently established to be of immediate clinical use [50, 51] . A combination of several sepsis biomarkers may be more effective but this requires further research [51] . Thus, the disconnect remains between the calls for early diagnosis/ treatment and the current diagnostic tools available.
Novel Pharmacological Agents
Similarly to biomarkers, there are a whole range of therapeutic agents described in the literature, but none are currently in routine clinical use [14] . One of the difficulties in translating promising laboratory results into clinical benefit is related to modelling. Animal models are frequently used but poorly replicate sepsis in humans [23] . Validated and more clinically relevant animal models are needed to understand the disease process and improve the selection of specific pathophysiological mechanisms [23] .
Nonetheless, there are a number of therapeutic agents that are being trialled targeting various inflammatory pathways, bacterial toxins or the endogenous immune system, and clinically applicable results are awaited by both researchers and clinicians. The ATHOS study (NCT02338843) is currently recruiting for a phase III trial looking at the use of angiotensin in catecholamine refractory shock. High-dose ascorbic acid, novel IgM-enriched immunoglobulin (NCT02655133) and L-carnitine (NCT01665092) are just some of the ongoing studies hoping to reveal new and clinically useful insights [52] [53] [54] .
Finally, endotoxin (lipopolysaccharide) is perhaps the best studied and one of the most potent initiators and mediators of the host response in sepsis. A variety of approaches have been tried to target endotoxin therapeutically, including extracorporeal devices to remove endotoxin. A recent press release by the company manufacturing these devices claims promising results but full publication is awaited [55].
Drugs to Facilitate and Maximize Recovery
It is increasingly recognized that survivors of intensive care suffer from significant physical, cognitive and psychological morbidity, referred to by some as the post-intensivecare syndrome [56] . Critical illness myopathy is a major complication and patients may face long-term disability. Its pathophysiology involves impaired myocyte excitability due to ion channel dysfunction, mitochondrial dysfunction, proteolysis and impaired protein, as well as calcium homeostasis [57] . These processes lead to disruption or loss of the contractile unit within the myocyte, a process that is exacerbated by axonal neuropathy. The pathophysiology of these mechanisms is thought to be triggered by inflammatory mediators, electrolyte and metabolic derangements, endocrine imbalances, steroids and disuse [57] .
For now, various non-pharmacological approaches to prevent muscle disuse are the main strategy, such as avoidance of sedation, weaning from mechanical ventilation, and early mobilization. There is current interest in tackling neuromuscular loss using optimized approaches to feeding (NCT02358512), and early translational work looking at molecular targets has been published [57, 58] . Overall, Sepsis-3 is unlikely to impact on neuromyopathy directly, other than earlier diagnosis and treatment of sepsis, which could ultimately lead to earlier recovery.
Concluding Remarks
Redefining syndromes creates exciting headlines and the new Sepsis-3 guidelines have been no different, highlighting the plight of patients with sepsis worldwide. Importantly, these latest definitions reflect the most current understanding of the pathogenesis of sepsis, emphasizing the role of the dysregulated host response following infection. Furthermore, the importance of early identification of both sepsis and the patients who have the greatest risk of deterioration is reiterated [1] . However, one of the main merits of this newest conceptual framework is an attempt to unify and codify the language of sepsis. Standardization of definitions and clinical criteria is crucial in enabling a consistent terminology in studies and clinical trials. Another possible benefit of more rigorous nomenclature is greater epidemiological accuracy. Figures around sepsis incidence and mortality vary hugely and greater clarity in defining sepsis is thought to be key in addressing this issue [1] . In particular, the overlap between SIRS criteria and infection is believed to have led to a large increase in sepsis diagnoses [59] . Despite potential benefits, the Sepsis-3 definitions have raised significant questions in the literature and have not been free of controversy.
• The new sepsis criteria aim to encompass all aspects of sepsis (infection, host response and organ dysfunction), while being easily measurable and applicable to all clinical areas [1] . However, as stated, the SOFA score offers little as a tool for patient management but merely characterizes the septic patient in the intensive care unit. It is a useful and well-known metric in the critical care environment for predicting mortality. Unfortunately, its role outside the intensive care unit seems less certain and, confusingly, is discussed under the heading 'Clinical criteria to identify patients with sepsis' [1] .
• The introduction of the quick SOFA (qSOFA; see Box 1) score has provoked considerable debate [59, 60] . It is crucial to appreciate that the qSOFA score is not part of the Sepsis-3 definition, but rather is an operational prompt conceived to identify patients with suspected infection who are likely to have poor outcomes. Again, questions arise as to how well an outcome prediction tool serves as a sepsis screen.
• Although Sepsis-3 acknowledges the lack of validation of the qSOFA tool, clinicians have questioned why, prior to promoting the use of a new tool, prospective modelling has not been undertaken [60, 61] .
• These deliberations are particularly pertinent given that, in non-critical care patients, SOFA and SIRS perform identically in predicting mortality, with an area under the curve of 0.79; 95% confidence interval (CI) 0.78-0.80 vs. 0.76; 95% CI 0.75-0.77 and sensitivities of 68 and 64%, respectively [1, 62] .
• Adopting new definitions and diagnostic criteria takes time as well as training, and very real concerns have been voiced regarding the management of sepsis while these new definitions are being both understood and implemented [61, 63] .
There is little doubt that redefining a heterogeneous concept such as sepsis, with its variable presentations and complex pathophysiological features, is a daunting task. In light of the existing controversies, the following understanding offers a pragmatic approach to the newest sepsis definitions:
1. In the face of new organ dysfunction, consider infection as a possible underlying cause. 2. Investigate the cause of organ dysfunction. 3. Sepsis management and referral to critical care where appropriate.
Nonetheless, both the clinical utility of the new Sepsis-3 definition and the future of SIRS remain to be seen and much of the struggle with sepsis continues, encapsulated in the two quotes below:
''Advances in the treatment of fever … have not kept pace with the rapid progress in our knowledge of the etiology. In the present condition of bacteriology we may expect great things in the near future, but meanwhile we jog along without any fixed aim, too often carried away by winds of doctrines and wild theories'' Osler [64] .
''As the physicians say it happens in hectic fever, that in the beginning of the malady it is easy to cure but difficult to detect, but in the course of time, not having been either detected or treated in the beginning, it becomes easy to detect but difficult to cure.'' (Niccolò Machiavelli, The Prince, 1532).
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